ASCO data suggest Mirati’s KRAS efficacy differentiation narrowing v. Lumakras

Mirati shares fell more than 20% in after-hours trading Thursday after new data reported at the American Society of Clinical Oncology meeting suggest the KRAS inhibitor’s efficacy profile may be less differentiated from the competition than initially thought.

In a data update from the company’s Phase II non-small cell lung cancer (NSCLC) study, Mirati Therapeutics Inc. (NASDAQ:MRTX) reported that KRAS G12C inhibitor adagrasib led to an ORR of 43% and a disease control rate of 80%. Medial PFS was 6.5 months...